229 related articles for article (PubMed ID: 30710146)
1. An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells.
Perotti V; Baldassari P; Molla A; Nicolini G; Bersani I; Grazia G; Benigni F; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2019 May; 38(22):4384-4396. PubMed ID: 30710146
[TBL] [Abstract][Full Text] [Related]
2. NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
Perotti V; Baldassari P; Molla A; Vegetti C; Bersani I; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2016 Jun; 35(22):2862-72. PubMed ID: 26387540
[TBL] [Abstract][Full Text] [Related]
3. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Souroullas GP; Jeck WR; Parker JS; Simon JM; Liu JY; Paulk J; Xiong J; Clark KS; Fedoriw Y; Qi J; Burd CE; Bradner JE; Sharpless NE
Nat Med; 2016 Jun; 22(6):632-40. PubMed ID: 27135738
[TBL] [Abstract][Full Text] [Related]
4. EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.
Zingg D; Debbache J; Peña-Hernández R; Antunes AT; Schaefer SM; Cheng PF; Zimmerli D; Haeusel J; Calçada RR; Tuncer E; Zhang Y; Bossart R; Wong KK; Basler K; Dummer R; Santoro R; Levesque MP; Sommer L
Cancer Cell; 2018 Jul; 34(1):69-84.e14. PubMed ID: 30008323
[TBL] [Abstract][Full Text] [Related]
5. Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy.
Yu H; Ma M; Yan J; Xu L; Yu J; Dai J; Xu T; Tang H; Wu X; Li S; Lian B; Mao L; Chi Z; Cui C; Guo J; Kong Y
J Transl Med; 2017 Dec; 15(1):243. PubMed ID: 29202777
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling.
Kruiswijk F; Hasenfuss SC; Sivapatham R; Baar MP; Putavet D; Naipal KA; van den Broek NJ; Kruit W; van der Spek PJ; van Gent DC; Brenkman AB; Campisi J; Burgering BM; Hoeijmakers JH; de Keizer PL
Oncogene; 2016 Apr; 35(17):2166-77. PubMed ID: 26279295
[TBL] [Abstract][Full Text] [Related]
7. AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy.
Puig-Butille JA; Vinyals A; Ferreres JR; Aguilera P; Cabré E; Tell-Martí G; Marcoval J; Mateo F; Palomero L; Badenas C; Piulats JM; Malvehy J; Pujana MA; Puig S; Fabra À
J Invest Dermatol; 2017 Jun; 137(6):1297-1310. PubMed ID: 28188776
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
[TBL] [Abstract][Full Text] [Related]
9. microRNA-216b inhibits cell proliferation and migration in human melanoma by targeting FOXM1 in vitro and in vivo.
Sun M; Wang X; Tu C; Wang S; Qu J; Xiao S
Cell Biol Int; 2017 Dec; 41(12):1272-1282. PubMed ID: 28225180
[TBL] [Abstract][Full Text] [Related]
10. CEACAM1 promotes melanoma metastasis and is involved in the regulation of the EMT associated gene network in melanoma cells.
Wicklein D; Otto B; Suling A; Elies E; Lüers G; Lange T; Feldhaus S; Maar H; Schröder-Schwarz J; Brunner G; Wagener C; Schumacher U
Sci Rep; 2018 Aug; 8(1):11893. PubMed ID: 30089785
[TBL] [Abstract][Full Text] [Related]
11. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
[TBL] [Abstract][Full Text] [Related]
12. NFATc2 is a potential therapeutic target in human melanoma.
Perotti V; Baldassari P; Bersani I; Molla A; Vegetti C; Tassi E; Dal Col J; Dolcetti R; Anichini A; Mortarini R
J Invest Dermatol; 2012 Nov; 132(11):2652-60. PubMed ID: 22718120
[TBL] [Abstract][Full Text] [Related]
13. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
[TBL] [Abstract][Full Text] [Related]
14. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P
Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929
[TBL] [Abstract][Full Text] [Related]
15. Effect of long non-coding RNA PVT1 on cell proliferation and migration in melanoma.
Chen L; Ma D; Li Y; Li X; Zhao L; Zhang J; Song Y
Int J Mol Med; 2018 Mar; 41(3):1275-1282. PubMed ID: 29286144
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA LOC554202 modulates chordoma cell proliferation and invasion by recruiting EZH2 and regulating miR-31 expression.
Ma X; Qi S; Duan Z; Liao H; Yang B; Wang W; Tan J; Li Q; Xia X
Cell Prolif; 2017 Dec; 50(6):. PubMed ID: 28963737
[TBL] [Abstract][Full Text] [Related]
17. siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
Chaudhary P; Yadav K; Lee HJ; Kang KW; Mo J; Kim JA
Breast Cancer Res; 2024 Apr; 26(1):72. PubMed ID: 38664825
[TBL] [Abstract][Full Text] [Related]
18. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
19. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
[TBL] [Abstract][Full Text] [Related]
20. EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells.
Zheng M; Cao MX; Luo XJ; Li L; Wang K; Wang SS; Wang HF; Tang YJ; Tang YL; Liang XH
J Cell Mol Med; 2019 Oct; 23(10):6942-6954. PubMed ID: 31368152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]